Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tesaro Inc (TSRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (MDXG , ESPR , TSRO , AIMT , FPRX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ESPR : 37.69 (-1.64%)
MDXG : 8.87 (-1.00%)
TSRO : 48.58 (+0.56%)
Tesaro Inc Shares Down 21.2% Since SmarTrend's Sell Call (TSRO)

SmarTrend identified a Downtrend for Tesaro Inc (NASDAQ:TSRO) on March 19th, 2018 at $61.31. In approximately 2 months, Tesaro Inc has returned 21.22% as of today's recent price of $48.30.

TSRO : 48.58 (+0.56%)
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

-- Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT

TSRO : 48.58 (+0.56%)
Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat

Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.

AZN : 36.88 (+0.11%)
CLVS : 47.52 (-1.55%)
TSRO : 48.58 (+0.56%)
BMY : 52.69 (+0.36%)
TESARO Announces First-Quarter 2018 Operating Results

-- ZEJULA Q1 net sales totaled $49 million

TSRO : 48.58 (+0.56%)
Tesaro Inc Has Returned 14.0% Since SmarTrend Recommendation (TSRO)

SmarTrend identified a Downtrend for Tesaro Inc (NASDAQ:TSRO) on March 19th, 2018 at $61.31. In approximately 1 month, Tesaro Inc has returned 13.96% as of today's recent price of $52.75.

TSRO : 48.58 (+0.56%)
TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA(R)

-- Results demonstrate ZEJULA activity beyond patients with BRCA mutations in late-line ovarian cancer treatment setting

TSRO : 48.58 (+0.56%)
New Research Coverage Highlights MPLX LP, TESARO, LKQ, Cytokinetics, Keysight Technologies, and Charles River Laboratories International -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MPLX LP (NYSE:MPLX), TESARO,...

CYTK : 8.75 (+0.57%)
LKQ : 30.07 (+1.01%)
KEYS : 53.44 (-0.28%)
MPLX : 35.75 (-1.52%)
TSRO : 48.58 (+0.56%)
CRL : 105.68 (-0.76%)
TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018

TESARO, Inc. (NASDAQ:TSRO) will announce first-quarter 2018 financial results on Thursday, May 3, 2018, after the close of the U.S. financial markets. TESARO's senior management team will host a conference...

TSRO : 48.58 (+0.56%)
Tesaro Inc Shares Down 9.5% Since SmarTrend's Sell Call (TSRO)

SmarTrend identified a Downtrend for Tesaro Inc (NASDAQ:TSRO) on March 19th, 2018 at $61.31. In approximately 4 weeks, Tesaro Inc has returned 9.46% as of today's recent price of $55.51.

TSRO : 48.58 (+0.56%)
Noteworthy Monday Option Activity: TSRO, ERI, WSM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tesaro Inc , where a total volume of 11,215 contracts has been traded thus far today,...

TSRO : 48.58 (+0.56%)
TESARO Summarizes TSR-042 Clinical Data Presented at AACR

-- Activity of TSR-042 (anti-PD-1 antibody) monotherapy demonstrated in patients with MSI-high endometrial and non-small cell lung cancers

TSRO : 48.58 (+0.56%)
TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA(R) in Israel

- Agreement covers all indications for ZEJULA, excluding prostate cancer

TSRO : 48.58 (+0.56%)
Look for Shares of Tesaro Inc to Potentially Rebound after Yesterday's 5.54% Sell Off

Tesaro Inc (NASDAQ:TSRO) traded in a range yesterday that spanned from a low of $51.22 to a high of $55.70. Yesterday, the shares fell 5.5%, which took the trading range below the 3-day low of $53.50...

TSRO : 48.58 (+0.56%)
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy

Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status....

AZN : 36.88 (+0.11%)
CLVS : 47.52 (-1.55%)
TSRO : 48.58 (+0.56%)
PFE : 35.89 (-0.22%)
Technical Perspectives on Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on TSRO, TRVN, VNDA, and VSTM which can be accessed for free by signing up to www.wallstequities.com/registration....

TRVN : 1.72 (-1.71%)
TSRO : 48.58 (+0.56%)
VNDA : 17.20 (+1.78%)
VSTM : 5.73 (+7.50%)
Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer

-- Efficacy of niraparib in combination with an anti-PD-1 mAb surpasses historical efficacy benchmarks for PD-1 or PARP monotherapies in difficult-to-treat types of ovarian cancer, regardless of biomarker...

TSRO : 48.58 (+0.56%)
Tesaro Inc Set to Possibly Rebound After Yesterday's Selloff of 6.06%

Tesaro Inc (NASDAQ:TSRO) traded in a range yesterday that spanned from a low of $55.77 to a high of $63.75. Yesterday, the shares fell 6.1%, which took the trading range below the 3-day low of $58.07...

TSRO : 48.58 (+0.56%)
Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug

Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

AZN : 36.88 (+0.11%)
HZNP : 15.52 (+1.37%)
CLVS : 47.52 (-1.55%)
TSRO : 48.58 (+0.56%)
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against TESARO, Inc. And Reminds Investors with Losses Exceeding $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 19, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TESARO, Inc. ("TESARO" or the...

TSRO : 48.58 (+0.56%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar